Interventions for Preventing the Progression of Autosomal Dominant Polycystic Kidney Disease
October 2024
in “
Cochrane Database of Systematic Reviews
”
Studysummary This review found that Tolvaptan is the only drug shown to slow the progression of autosomal dominant polycystic kidney disease, but it does not affect mortality or kidney failure outcomes.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This review evaluates interventions for preventing the progression of autosomal dominant polycystic kidney disease (ADPKD). Despite numerous studies, there is limited evidence that most interventions improve patient outcomes. Tolvaptan is the only treatment shown to slow disease progression by affecting eGFR and TKV, but it does not impact mortality or kidney failure. Other interventions, such as somatostatin analogues and targeted blood pressure management, have uncertain effects and may cause adverse events like alopecia and fatigue. The review highlights the need for large randomized controlled trials focusing on patient-centered outcomes to better understand the efficacy of various treatments. Additionally, 23 ongoing studies, including larger phase III trials, may offer further insights in future updates.
